PERIPHERAL T CELL LYMPHOMA

This study tests whether adding either Beleodaq or Folotyn to standard chemotherapy (CHOP) helps people with newly diagnosed peripheral T-cell lymphoma live longer without their cancer getting worse. About 504 participants will be randomly assigned to one of three treatment group…

This study tests an experimental drug called HH2853 for people with certain types of blood cancer (non-Hodgkin's lymphoma) or advanced solid tumors that have come back or not responded to other treatments. The goal is to find the safest dose and see if the drug can shrink tumors.…

This study tests a new drug called golidocitinib against standard treatments for adults with a rare blood cancer (peripheral T-cell lymphoma) that has returned or stopped responding to prior therapy. About 218 participants will be randomly assigned to receive either golidocitinib…

This study tests a new treatment for people with a rare blood cancer (peripheral T-cell lymphoma) that has not responded to standard therapy or has returned. Researchers take a patient's own immune cells, modify them in a lab to recognize and attack cancer cells, and then infuse …

This study looks at people with peripheral T-cell lymphoma whose cancer went away after their first treatment. It compares two options: getting a stem cell transplant using their own cells or simply watching and waiting. The goal is to see which approach helps keep the cancer awa…

This program provides the experimental drug selinexor to people with multiple myeloma, lymphoma, sarcoma, or other cancers who have run out of standard treatments and cannot join a clinical trial. Patients must get approval from their doctor and local health authorities. The goal…

This study tests whether combining two drugs—sintilimab and chidamide—can help people with a type of blood cancer called peripheral T-cell lymphoma that has come back or not responded to prior treatment. About 51 adults aged 18 to 75 will receive the combination therapy. The goal…

This study tests whether a combination of two drugs, cidabenamine and azacitidine, can prevent high-risk peripheral T-cell lymphoma from progressing after a stem cell transplant. About 40 adults aged 18-70 will receive this maintenance therapy. The goal is to improve survival and…

This study looks at two stem cell transplant methods for people with peripheral T-cell lymphoma whose cancer only partially shrank after first treatment. One method uses the patient's own stem cells, the other uses a donor's stem cells. The goal is to see which approach works bet…

This study tests a new treatment for people with CD30-positive lymphomas (like Hodgkin lymphoma) that have come back or not responded to standard therapy. The treatment uses immune cells from healthy donors that are modified to better target and kill cancer cells, plus a safety s…

This study tests whether adding a JAK inhibitor (ruxolitinib) to an immunotherapy drug (pembrolizumab) is safe and effective for people with certain types of lymphoma that have come back or not responded to treatment. About 53 adults with Hodgkin or non-Hodgkin lymphoma will take…

This early-phase trial tests whether a patient's own immune cells, modified in a lab to recognize and attack a protein called CCR4 on cancer cells, can safely treat certain types of T-cell lymphoma that have not responded to standard therapy. About 60 adults with relapsed or refr…

This study tests whether combining the drug golidocitinib with either mitoxantrone liposome or chidamide can safely shrink tumors in people with peripheral T-cell lymphoma that has returned or not responded to prior therapy. About 101 adults will take part. The goal is to find th…

This study is for people with peripheral T-cell lymphoma whose cancer did not shrink or got worse after standard first treatment. It compares a stem cell transplant from a donor to other treatment options. The goal is to see which approach helps people live longer. About 58 adult…

This study tests a new drug called CCS1477 in people with advanced blood cancers like leukemia, lymphoma, and multiple myeloma. The goal is to see if the drug is safe and helps shrink tumors. About 250 adults who have already tried standard treatments will take part.

This study tests a new combination of two targeted drugs (linperlisib and chidamide) against standard chemotherapy (CHOP) for people with a rare type of blood cancer called peripheral T-cell lymphoma. The trial has three parts: first, finding the best dose; second, checking how w…

This study tests a new type of CAR-T cell therapy that targets two cancer markers at once, designed to work better when standard treatments have failed. About 96 adults with various relapsed or refractory blood cancers will receive an infusion of these engineered immune cells. Th…

This study tests whether the drug ruxolitinib can help prevent T-cell lymphoma from coming back and reduce graft-versus-host disease (GVHD) after a stem cell transplant. About 44 adults with certain types of T-cell lymphoma who are in remission after transplant will take ruxoliti…

This study tests a new drug called golidocitinib, given alone or with standard chemotherapy (CHOP), for people newly diagnosed with peripheral T-cell lymphoma, a rare blood cancer. The goal is to see if the drug can help control the disease. About 30 adults will take part at MD A…

This early-stage trial tests a new drug called ST-001 (a form of fenretinide) in people with T-cell non-Hodgkin lymphoma that has returned or not responded to prior treatments. The main goal is to find the safest dose and understand side effects. About 46 adults with specific typ…

This early-phase trial tests a specially modified virus (VSV-hIFNβ-NIS) combined with an immunotherapy drug (cemiplimab) in adults with relapsed or refractory T-cell lymphoma. The virus is designed to kill cancer cells while leaving healthy cells alone, and the immunotherapy help…

This study tests whether adding the drug lacutamab to standard chemotherapy (GemOx) helps control peripheral T-cell lymphoma that has come back or not responded to treatment. About 56 adults with a specific marker (KIR3DL2) on their cancer cells will receive either the combinatio…

This study tests whether the drug golidocitinib can help keep peripheral T-cell lymphoma from coming back after initial chemotherapy. It is for patients who had a good response to their first treatment but cannot have a stem cell transplant. Participants take either golidocitinib…

This study looks at how the body handles venetoclax when the tablet is crushed and mixed into a liquid for children and young adults with blood cancers like leukemia or lymphoma. It includes 30 people under 39 who already need a central line for blood draws. The goal is to find o…

This study is watching how 3000 people with peripheral T-cell lymphoma are treated in regular clinics and how they do over time. It aims to learn which treatments work best, find patterns in the disease, and discover why some patients relapse. No new drugs are tested—just careful…